Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln

Polypid

12/11/2025 12:38

Overview

PolyPid reports Q3 net loss of $7.5 mln, down from $7.8 mln last year

Company advances regulatory strategy with pre-NDA meeting scheduled for December

PolyPid progresses in U.S. partnership talks post positive Phase 3 trial results

Outlook

PolyPid plans NDA submission for D-PLEX₁₀₀ in early 2026

Company advancing U.S. partnership discussions for D-PLEX₁₀₀

PolyPid expects cash balance to fund operations into 2026

Result Drivers

R&D - The increase in R&D expenses was primarily due to activities related to the completion of the SHIELD II Phase 3 trial and preparation for regulatory submissions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
$0.37
Q3 Net Income
$7.45 mln
Q3 Operating Income
$7.46 mln
Q3 Pretax Profit
$7.43 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for PolyPid Ltd is $13.00, about 71.1% above its November 11 closing price of $3.76

Press Release: ID:nGNX9rSTFN

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)